Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

ACR was a key indicator of risk for mortality in RA with chronic renal insufficiency, predicting all-cause mortality better than eGFR.

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Scientists conducted a simulation study to estimate the impact of cardiovascular-kidney-metabolic (CKM) syndrome on cardiovascular disease (CVD) risk prediction. The study found that adults with ...

People with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

Severe coronary artery calcification in patients with CKD increases the risk for heart failure, heart valve calcification, and progression to kidney failure.

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Inc., together with Dialysis Philippines Support Group (Dialysis PH), Kidney Transplant Association of the Philippines (KITAP ...